We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. The phase 3 BOREAS trial included adults with ...

Bhatt’s study, "Dupilumab for COPD with Type 2 Inflammation Indicated by Eosinophil Counts,” was recently published in The New England Journal of Medicine. Bhatt and colleagues conducted a multicenter ...

Dupilumab significantly reduced exacerbations and improved lung function in adults with uncontrolled chronic obstructive pulmonary disease (COPD) and type 2 inflammation, based on data from more than ...

Use of biologics significantly reduced exacerbations and hospitalizations in adults with chronic obstructive pulmonary disease (COPD) and overlapping type 2 asthma inflammation, based on data from a ...

These improvements — as measured by a significantly lower annualized rate of acute exacerbations, significantly better lung function and quality of life, and significantly less severe symptoms than ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Receipt of an SGLT-2 inhibitor for type 2 diabetes in ...

Chronic obstructive pulmonary disease (COPD) is characterized by a chronic airflow obstruction that is associated with severe global mortality and morbidity. A team of researchers from USA, led by ...

In the phase 3 BOREAS study of patients with chronic obstructive pulmonary disease (COPD) and type 2 inflammation, patients treated with dupilumab experienced fewer COPD exacerbations, improved lung ...

"The key finding as a clinician is to recognize that severe COPD patients have heterogeneity in terms of biological processes, which likely explains variable clinical courses and responses to ...

A lung disease impacting more than 16 million Americans has no long-term fix, but a new treatment could help. Piedmont Atlanta is the first hospital in Georgia to offer a new, minimally invasive ...